A tumor microenvironment model of chronic lymphocytic leukemia enables drug sensitivity testing to guide precision medicine
Johanne U. Hermansen(Oslo University Hospital), Sigrid S. Skånland(Oslo University Hospital)
Cited by 17
Related Papers
COVID-19 in patients with CLL: improved survival outcomes and update on management strategies
|Blood|2021|70
Phosphoinositide‐Regulated Retrograde Transport of Ricin: Crosstalk Between hVps34 and Sorting Nexins
|Traffic|2006|60
PI3K Inhibitors in Hematology: When One Door Closes…
|Clinical Cancer Research|2024|23
Standardized assays to monitor drug sensitivity in hematologic cancers
|Cell Death Discovery|2023|17
Mcl‐1 and Bcl‐xL levels predict responsiveness to dual MEK/Bcl‐2 inhibition in B‐cell malignancies
|Molecular Oncology|2021|16